Drugs that contain Fenfluramine Hydrochloride

1. List of Fintepla drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10947183 ZOGENIX INC Fenfluramine compositions and methods of preparing the same
Dec, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549909 ZOGENIX INC Method for the treatment of dravet syndrome
May, 2033

(10 years from now)

US10478442 ZOGENIX INC Method for the treatment of Dravet Syndrome
May, 2033

(10 years from now)

US10478441 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(10 years from now)

US9603815 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(10 years from now)

US9610260 ZOGENIX INC Method for the treatment of Dravet Syndrome
May, 2033

(10 years from now)

US9603814 ZOGENIX INC Method for the treatment of Dravet syndrome
May, 2033

(10 years from now)

US9603815

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(10 years from now)

US10478441

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(10 years from now)

US10478442

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet Syndrome
Nov, 2033

(10 years from now)

US9603814

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet syndrome
Nov, 2033

(10 years from now)

US9610260

(Pediatric)

ZOGENIX INC Method for the treatment of Dravet Syndrome
Nov, 2033

(10 years from now)

US9549909

(Pediatric)

ZOGENIX INC Method for the treatment of dravet syndrome
Nov, 2033

(10 years from now)

US10950331 ZOGENIX INC Control system for control of distribution of medication
Sep, 2035

(12 years from now)

US10950331

(Pediatric)

ZOGENIX INC Control system for control of distribution of medication
Mar, 2036

(13 years from now)

US10947183

(Pediatric)

ZOGENIX INC Fenfluramine compositions and methods of preparing the same
Jun, 2037

(14 years from now)

US10603290 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

US11040018 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

US11406606 ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Aug, 2037

(14 years from now)

US11040018

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US11406606

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US10603290

(Pediatric)

ZOGENIX INC Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
Feb, 2038

(15 years from now)

US10452815 ZOGENIX INC Control system for control of distribution of medication
Jun, 2038

(15 years from now)

US10452815

(Pediatric)

ZOGENIX INC Control system for control of distribution of medication
Dec, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 25, 2027
New Product (NP) Jun 25, 2023
New Indication (I) Mar 25, 2025
Pediatric Exclusivity (PED) Dec 25, 2027

Market Authorisation Date: 25 June, 2020

Treatment: Use in combination with stiripentol, valproate, and clobazam for the treatment of seizures associated with dravet syndrome; Use in combination with stiripentol for the treatment of seizures associated with dravet syndrome; Treatment of refractory epilepsy patients with fenfluramine that reduces the risk of cardiovascular toxicity by using cardiac monitoring and restricted distribution; Use in combination with cannabidiol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with dravet syndrome; Use of fenfluramine at reduced amounts with stiripentol for the treatment of seizures associated with lennox gastaut syndrome; Use of cardiac monitoring and restricted distribution of fenfluramine to mitigate risk of cardiovascular toxicity in the treatment of seizures associated with dravet syndrome

Dosage: SOLUTION;ORAL

How can I launch a generic of FINTEPLA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic